Metformin, a common antidiabetic drug, has been repeatedly shown to possess a cardioprotective role in permanent myocardial infarction (MI) [15], ischemia/reperfusion (I/R) injury [16] and hypertrophy [17], not only via its antidiabetic effects but also through the activation of AMPK. The gene discussed is PRKAA1; the disease is myocardial infarction.